Yun Yen - Jun 30, 2025 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role
Director
Signature
/s/ Yun Yen
Stock symbol
LIXT
Transactions as of
Jun 30, 2025
Transactions value $
$0
Form type
4
Date filed
7/9/2025, 11:52 AM
Previous filing
Apr 2, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Yen Yun Director 680 E. COLORADO BLVD., SUITE 180, PASADENA /s/ Yun Yen 2025-07-09 0001684584

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIXT Options to Purchase Common Stock Award $0 +10K $0.00 10K Jun 30, 2025 Common 10K $0.91 Direct F1
transaction LIXT Options to Purchase Common Stock Award $0 +11.6K $0.00 11.6K Jun 30, 2025 Common 11.7K $0.91 Direct F2
holding LIXT Options to Purchase Common Stock 8.78K Jun 30, 2025 Common 8.78K $1.21 Direct
holding LIXT Options to Purchase Common Stock 4.55K Jun 30, 2025 Common 4.55K $2.33 Direct
holding LIXT Options to Purchase Common Stock 5.79K Jun 30, 2025 Common 5.79K $1.30 Direct
holding LIXT Options to Purchase Common Stock 10K Jun 30, 2025 Common 10K $2.37 Direct
holding LIXT Options to Purchase Common Stock 4.53K Jun 30, 2025 Common 4.53K $2.37 Direct
holding LIXT Options to Purchase Common Stock 10K Jun 30, 2025 Common 10K $7.45 Direct
holding LIXT Options to Purchase Common Stock 10K Jun 30, 2025 Common 10K $30.30 Direct
holding LIXT Options to Purchase Common Stock 5K Jun 30, 2025 Common 5K $32.10 Direct
holding LIXT Warrants to Purchase Common Stock 5.26K Jun 30, 2025 Common 5.26K $57.00 By Sino-American Cancer FDD
holding LIXT Options to Purchase Common Stock 3.33K Jun 30, 2025 Common 3.33K $16.80 Direct
holding LIXT Options to Purchase Common Stock 833 Jun 30, 2025 Common 833 $66.00 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective June 30, 2025, the reporting person was granted stock options to purchase an aggregate of 10,000 shares vesting in eight equal installments on the last day of each subsequent quarter until fully vested with vesting to start on September 30, 2025.
F2 Effective June 30, 2025 the reporting person was granted stock options in aggregate of 11,632 vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.